The string of megadeals announced in the first half of 2024 reflect a growing confidence among US dealmakers. But can the bull run be sustained?
Megadeals were firmly on the agenda in H1 as more stable inflation and...more
9/30/2024
/ Acquisitions ,
Buyers ,
Capital Markets ,
Domestic Dealmaking ,
Global Dealmaking ,
Investment ,
Investors ,
Lenders ,
Mergers ,
Regulatory Agenda ,
Sellers
Global M&A activity continued to make slow progress in 2023, with stubbornly high interest rates and stringent financing conditions stifling market confidence. Nearly US$3.2 trillion of M&A deals were announced last year—a...more
2/16/2024
/ Acquisitions ,
Buyers ,
Capital Markets ,
Competition ,
EU ,
Federal Trade Commission (FTC) ,
Global Dealmaking ,
Investment ,
Investors ,
Mergers ,
Private Equity ,
Sellers ,
Technology
Declining consumer spending power is driving down revenues and pushing luxury firms to seek new avenues for growth -
Slowing economic growth, hampered by stubborn inflation, has inhibited consumer confidence across the...more
Ongoing uncertainty hampers dealmaking in second quarter of the year, but mining megadeals and the race for clean energy offer a ray of hope.
Global dealmakers had a lot to contend with in the second quarter of this year....more
8/15/2023
/ Acquisitions ,
Buyers ,
EU ,
Global Dealmaking ,
Global Market ,
Investment ,
Investors ,
Mergers ,
Private Equity Firms ,
Private Equity Funds ,
Sellers
Against the odds, dealmakers put in a solid performance in 2022, but this year has seen a slow start as buyers in the US M&A market clamor for much needed regulatory clarity -
Global M&A markets gave both optimists and...more
After a year of historic profits in 2021 following the mass roll-out of COVID-19 vaccines and related treatments, big pharma companies armed with cash for deals have been shifting their attention -
Overall, pharma, medical...more
2/3/2023
/ Acquisitions ,
Biotechnology ,
Coronavirus/COVID-19 ,
Global Dealmaking ,
Healthcare ,
Investment ,
Investors ,
Life Sciences ,
Mergers ,
Pharmaceutical Industry ,
Prescription Drugs ,
Vaccinations
After reaching unprecedented highs in 2021, global M&A markets had a bumpy ride in 2022 as dealmakers grappled with inflation, rising interest rates and fallout from the conflict in Ukraine.
Deal value for 2022 came in...more
Although the record-breaking deal activity of 2021 spilled over into 2022, headwinds in the first quarter developed into a significant slowdown during the rest of 2022, with an expectation of continued slowness as we enter...more
1/30/2023
/ Acquisitions ,
Buyers ,
Capital Markets ,
CFIUS ,
Coronavirus/COVID-19 ,
Cryptocurrency ,
Department of Justice (DOJ) ,
Domestic Dealmaking ,
Environmental Social & Governance (ESG) ,
EU ,
Federal Trade Commission (FTC) ,
Financial Institutions ,
Financial Services Industry ,
Global Dealmaking ,
Investment ,
Investors ,
Mergers ,
Pharmaceutical Industry ,
Private Equity ,
Publicly-Traded Companies ,
Real Estate Market ,
Securities and Exchange Commission (SEC) ,
Sellers ,
Special Purpose Acquisition Companies (SPACs) ,
Technology
M&A started strong in 2022 with robust deal activity and megadeals dominating the landscape that was largely the result of unprecedented spillover from 2021. But then, things took a turn and deals stalled in the second half...more
Following on from two robust first quarters, global M&A activity succumbed to prolonged market uncertainty in the third quarter. A total of 5,163 deals worth a total of US$731.3 billion changed hands during the quarter...more
As predicted in our previous M&A report, 2022 has not lived up to the runaway performance of 2021. As activity—still at impressive levels considering everything that has been thrown at the deal market—takes a breather, we...more
9/13/2022
/ Acquisitions ,
Buyers ,
Capital Markets ,
Domestic Dealmaking ,
EBITDA ,
Global Dealmaking ,
High Yield Bonds ,
Interest Rates ,
Leveraged Loans ,
Mergers ,
Private Equity
Technology, media and telecoms (TMT) continued its reign as the dominant sector for US M&A in the first half of 2022, despite a year-on-year collapse in the value of media and telecoms deals. Technology remains at the core of...more
Explore the data The headline for the first half of 2022 is that US M&A markets are still remarkably healthy, despite a confluence of headwinds. Without question, 2021 was an exceptional year, fueled by pent-up demand,...more
8/23/2022
/ Acquisitions ,
Capital Markets ,
Deal Price ,
Domestic Dealmaking ,
EBITDA ,
Environmental Social & Governance (ESG) ,
Fair Market Value ,
Global Dealmaking ,
Greenwashing ,
Market Price ,
Mergers ,
Popular ,
Private Equity ,
Publicly-Traded Companies ,
Special Purpose Acquisition Companies (SPACs)
Dealmaking failed to reach the highs of the previous year as rising inflation and a challenging financing environment put some deals under question -
Global dealmaking continued its bumpy return to pre-pandemic levels in...more
While global dealmaking in Q1 was down from a blockbuster 2021, there are signs deal activity could pick up later in the year -
Following a record-breaking year for dealmaking, 2022 has had a relatively slow start. A total...more
4/8/2022
/ Acquisitions ,
Activision ,
Banking Sector ,
Canada ,
Coronavirus/COVID-19 ,
Gaming ,
Global Dealmaking ,
Global Market ,
Investment ,
Investors ,
Mergers ,
Real Estate Market ,
Software ,
Technology ,
Video Games
Dealmakers in almost every industry had an outstandingly busy 2021. With just a few exceptions, the M&A boom swept across the US economy with deal values, in particular, up significantly on 2020 totals.
Nevertheless,...more
2/18/2022
/ Acquisitions ,
Biotechnology ,
Capital Markets ,
Domestic Dealmaking ,
Energy Sector ,
Financial Services Industry ,
Healthcare ,
Investment ,
Investors ,
Mergers ,
Pharmaceutical Industry ,
Retail Market ,
Technology Sector
M&A markets appeared to defy gravity through 2021. Globally, dealmakers were highly active, with values exceeding US$5 trillion for the first time ever. Total deal value rose by 81 percent on 2020 totals to US$5.75 trillion,...more
Five factors that will shape dealmaking over the coming 12 months -
Last year will be a very tough act to follow. M&A values and volumes soared on the back of confident public markets, strong deal financing options and a...more
2/7/2022
/ Acquisitions ,
Coronavirus/COVID-19 ,
Domestic Dealmaking ,
Federal Trade Commission (FTC) ,
Interest Rates ,
Mergers ,
Private Equity ,
Regulatory Oversight ,
Securities and Exchange Commission (SEC) ,
Special Purpose Acquisition Companies (SPACs) ,
Stock Markets
Global dealmaking was consistently strong in 2021, with the value topping US$1 trillion in each quarter for the first time on record. This achievement is particularly impressive given the tumultuous deal environment, as M&A...more
Heightened interest in medical suppliers, contract research organizations and biotech firms resulted in an impressive year for healthcare dealmaking-
Dealmaking within the pharma, medical and biotech sector continued from...more
12/21/2021
/ Acquisitions ,
Biotechnology ,
Coronavirus/COVID-19 ,
Domestic Dealmaking ,
Healthcare ,
Investment ,
Investors ,
Life Sciences ,
Medical Research ,
Mergers ,
Special Purpose Acquisition Companies (SPACs) ,
Technology
Despite a drop on the previous quarter, Q3 2021 global M&A value represented the strongest Q3 on Mergermarket record -
The third quarter is usually a sleepy one for M&A—but not so this year. A total of US$1.4 trillion in...more
After a turbulent 18 months which saw M&A crash before an impressive return to form, H2 2021 is set for continued strong deal activity, as well as new challenges -
US M&A progressed steadily through the first half of 2021....more
8/10/2021
/ Acquisitions ,
Biden Administration ,
CFIUS ,
Coronavirus/COVID-19 ,
Domestic Dealmaking ,
Enforcement ,
Global Dealmaking ,
Investment ,
Liquidity ,
Mergers ,
National Security ,
Securities and Exchange Commission (SEC) ,
Special Purpose Acquisition Companies (SPACs) ,
Stock Markets ,
Technology Sector ,
Vaccinations
Healthy deal activity has returned to the leisure and retail sectors—areas of the economy that were among the worst affected by the pandemic.
Together, the leisure and retail sectors saw M&A value reach US$41.7 billion...more
A brightening macroeconomic outlook and supportive deal environment helped push second-quarter value to a new record
Dealmakers hoping for a 2021 rebound in M&A activity have not been disappointed. In Q2 2021, M&A value...more
Dealmaking within the PMB sector enjoyed an impressive start as companies across the globe embarked on their post-pandemic recovery -
The global pharma, medical and biotech (PMB) sector saw US$95.4 billion in deal...more